Drug intelligence / Profile preview

AVB-301

Development stage: Preclinical
Lead developer: AviadoBio
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Ophthalmic

Overview

AVB-301 is an investigational gene therapy being developed by AviadoBio for the treatment of inherited retinal dystrophies (IRDs). The program leverages AviadoBio's expertise in adeno-associated virus (AAV) vector technology and specialized delivery platforms to address the underlying genetic causes of retinal degeneration. While the specific molecular target and clinical phase have not been publicly disclosed, the therapy is designed to provide a durable therapeutic effect by delivering a functional transgene to retinal cells, likely via intravitreal administration. AVB-301 is part of a broader pipeline at AviadoBio focused on neurodegenerative and ophthalmic diseases using proprietary delivery and RNA silencing systems.

Beyond the preview

Go deeper on AVB-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVB-301.

Explore the full profile